Docetaxel
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Docetaxel是源自欧洲红豆杉树浆果的新型紫杉烷家族成员,是一种有效的化学治疗剂,它作为纺锤体毒素通过促进微管的组装和稳定聚合物进而抑制微管动力学和细胞周期停滞。在体和离体实验中,Docetaxel表现出强烈的抗肿瘤活性,包括乳腺癌、肺癌、卵巢癌、头颈部和胃癌。研究表明,在卵巢癌细胞系中,与其他化学治疗剂相比,Docetaxel具有更强的细胞毒性,其中,Docetaxel的细胞毒性比紫杉醇大1.2到2.6倍,比顺铂或依托泊苷大超过1000倍。
参考文献:
N Katsumata. Docetaxel: an alternative taxane in ovarian cancer. British Journal of Cancer (2003) 89 (Suppl 3), S9-S15
- 1. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022.
- 2. Weibo Zhong, Kaihui Wu, et al. "Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis." Microbiome. 2022 Jun 16;10(1):94. PMID: 35710492
- 3. Mikhail S. Chesnokov, Marianna Halasi, et al. "Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells." Cell Death Dis. 2021 Jul 14;12(7):704. PMID: 34262016
- 4. Robert Craig Peery. "Optimization of Survivin Dimerization Inhibitors for the Treatment of Docetaxel-Resistant Prostate Cancer." January 2020.
- 5. Yan L, Ding B, et al. "Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma." Theranostics. 2019 Oct 22;9 (26):8377-8391. PMID: 31754403
- 6. Zhang Y, Xia F, et al. "miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2." J Exp Clin Cancer Res. 2019 Jan 21;38(1):26. PMID: 30665445
- 7. Li Q, Deng Q, et al. "Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses." Nat Commun. 2018 Sep 6;9(1):3600. PMID: 30190514
- 8. Zhou XW, Xia YZ, et al. "Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling. Oncotarget." 2017 Oct 19;8(60):101965-101983. PMID: 29254218
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 807.88 |
Cas No. | 114977-28-5 |
Formula | C43H53NO14 |
Synonyms | Taxotere, Docetaxel anhydrous, Trihydrate |
Solubility | ≥40.4 mg/mL in DMSO; insoluble in H2O; ≥94.4 mg/mL in EtOH |
SDF | Download SDF |
Canonical SMILES | O=C(N[C@H]([C@H](C(O[C@H]1C[C@]2(O)C(C)(C)C([C@@H](O)C([C@@]3(C)[C@]([C@@](CO4)(OC(C)=O)[C@@]4([H])C[C@@H]3O)([H])[C@@H]2OC(C5=CC=CC=C5)=O)=O)=C1C)=O)O)C6=CC=CC=C6)OC(C)(C)C |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验 [1]: | |
细胞系 |
9种人胃癌细胞系 |
制备方法 |
在DMSO中的溶解度大于10 mM。若配制更高浓度的溶液,一般步骤如下:请将试管置于37 °C加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20 °C可放置数月。 |
反应条件 |
< 0.00012 ~ > 1.2 μM |
实验结果 |
在9种人胃癌细胞系中,Docetaxel对其中6种细胞显示出较强的细胞毒性(相对于Paclitaxel)。相对于其它7种细胞系,Docetaxel和Paclitaxel对MM-7和ST-SA-1细胞的影响相对较少。 |
动物实验 [1]: | |
动物模型 |
携带人胃癌异种移植瘤(MKN-28、MKN-45和KKLS)的小鼠模型 |
给药剂量 |
3.75、7.5、15或22 mg/kg;静脉注射;每4天注射3次 |
实验结果 |
Docetaxel呈剂量依赖性抑制肿瘤生长。对于所有小鼠,在剂量为15和22 mg/kg时,Docetaxel诱导肿瘤完全消退。 |
其它注意事项 |
请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同,但仍处于实验系统误差的允许范围内。 |
References: [1]. Tanaka M, Obata T, Sasaki T. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer. 1996 Feb;32A(2):226-30. |
描述 | Docetaxel是一种紫杉醇的类似物,通过结合到稳定的微管抑制微管解聚。 | |||||
靶点 | Microtubules | |||||
IC50 |
质量控制和MSDS
- 批次: